By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.

Unique Investment Opportunity

Global rev. for treatment
€ 20 Bio.
Forecast for 2031
€ 30,4 Bio.
Social Burden Europe
€ 200 Bio.

Fueling growth with data Insights

Company Valuation
€ 150 Mio.
Ticket Size
€ 1-3 Mio.
First Returns
2027

Fundraising

Executive Summary
Concise overview of the problem and our unique solution, offering a brief yet comprehensive summary of the key points.
Executive Summary (DE)
Concise overview of the problem and our unique solution, offering a brief yet comprehensive summary of the key points.
Pitch Deck
Detailed presentation that outlines the essential aspects of our project.
CV - Prof. Dr. Rolf Ziesche
Explore the journey and expertise behind the visionary leader shaping Transgenion's innovative strides in CID research.
CORE 1

First personalized diagnosis for progressive COPD

The CORE 1 program makes use of the targets characterizing the core mechanisms of COPD development and will achieve authority approval for the first predicitive diagnosis of COPD, a quantum leap and game changer in the field of chronic inflammatory diseases.

The completion of CORE-1 marks the equivalent pharmaceutical development value at € 450 Mio.

The Transgenion Advantage

Currently at Technical Readiness Level 6

TRL
1
TRL
2
TRL
3
TRL
4
TRL
5
TRL 6
Technology demonstrated in relevant environment
Successful Clinical Pilot Study

Complete analysis for all clinically relevant markers in lung tissue based on 3-year observation per subject, representing COPD progression over more than 30 years.

Sequential Recording

First-time sequential recording of all relevant markers throughout the entire COPD course (from the risk stage to end-stage).

Unique Dataset

Unique dataset fully patented (25 patents across US, Europe and Japan).

>10 Years Market Lead

In summary, this results in a market lead of at least 10 years.

Financial Forecast - CORE 1

Unique Investment Opportunity

Work Package 1 - First Returns in 2027

Confirmation trial for first clinically validated diagnostic COPD Test.

Fix Cost
€ 5,27 Mio.
Package-specific costs
€ 21,2 Mio.
Return - Equity Sale
€ 100 Mio.

Work Package 2 - Return in 2028

Validation of Targets, pre-clinicial data set and therapeutic compounds

Fix Cost
€ 5,27 Mio.
Package-specific costs
€ 10,3 Mio.
Return - Equity Sale
€ 80 Mio.

Work Package 3 - Return in 2029

Application trial for first clinically validated diagnostic test for COPD

Fix Cost
€ 5,27 Mio.
Package-specific costs
€ 16,7 Mio.
Return - Equity Sale
€ 270 Mio.

Additional Information

Starting with the CORE Programs, Transgenion is realizing the first useful diagnosis and causal treatment for CID.

Unique Dataset of Worldwide Patents - US, Europe & Japan
Publication number
Patent number
Country
Status
Priority Date
Filing Date
Grant Date
US 2017/0107574 A1
US-10508307-B2
US
Granted
Jun 05, 2014
Jun 03, 2015
Dec 17, 2019
US 2017/0349947 A1
US-10526656-B2
US
Granted
Jun 05, 2014
Jun 03, 2015
Jan 07, 2020
US 2017/0335393 A1
US-10526656-B2
US
Granted
Jun 05, 2014
Jun 03, 2015
Mar 21, 2020
US 2020/0017914 A1
US-11124835-B2
US
Granted
Jun 05, 2014
Jun 03, 2015
Sep 21, 2021
EP 3152330 A1
EP-3152330-B1
EU
Granted
Jun 05, 2014
Jun 03, 2015
Jan 27, 2021
EP 3152330 A1
E-1358389
EU/AT
Granted
Jun 05, 2014
Jun 03, 2015
Jan 27, 2021
EP 3152330 A1
EP-3152330-B1
EU/BE
Granted
Jun 05, 2014
Jun 03, 2015
Jan 27, 2021
EP 3152330 A1
EP-3152330-B1
EU/CH
Granted
Jun 05, 2014
Jun 03, 2015
Jan 27, 2021
EP 3152330 A1
EP-3152330-B1
EU/CZ
Granted
Jun 05, 2014
Jun 03, 2015
Jan 27, 2021
EP 3152330 A1
DE 60 2015 065 227 4
EU/DE
Granted
Jun 05, 2014
Jun 03, 2015
Jan 27, 2021
EP 3152330 A1
EP-3152330-B1
EU/DK
Granted
Jun 05, 2014
Jun 03, 2015
Jan 27, 2021
EP 3152330 A1
EP-3152330-B1
EU/ES
Granted
Jun 05, 2014
Jun 03, 2015
Jan 27, 2021
EP 3152330 A1
EP-3152330-B1
EU/FR
Granted
Jun 05, 2014
Jun 03, 2015
Jan 27, 2021
EP 3152330 A1
EP-3152330-B1
EU/GB
Granted
Jun 05, 2014
Jun 03, 2015
Jan 27, 2021
EP 3152330 A1
EP-3152330-B1
EU/IE
Granted
Jun 05, 2014
Jun 03, 2015
Jan 27, 2021
EP 3152330 A1
EP-3152330-B1
EU/IT
Granted
Jun 05, 2014
Jun 03, 2015
Jan 27, 2021
EP 3152330 A1
EP-3152330-B1
EU/NL
Granted
Jun 05, 2014
Jun 03, 2015
Jan 27, 2021
EP 3152330 A1
EP-3152330-B1
EU/NO
Granted
Jun 05, 2014
Jun 03, 2015
Jan 27, 2021
EP 3152330 A1
EP-3152330-B1
EU/PL
Granted
Jun 05, 2014
Jun 03, 2015
Jan 27, 2021
EP 3152330 A1
EP-3152330-B1
EU/SE
Granted
Jun 05, 2014
Jun 03, 2015
Jan 27, 2021
EP 3152330 A1
EP-3152330-B1
EU/SK
Granted
Jun 05, 2014
Jun 03, 2015
Jan 27, 2021
EP 3152330 A1
EP-3152330-B1
EU/TR
Granted
Jun 05, 2014
Jun 03, 2015
Jan 27, 2021
JP 2017 516195
JP 2017-519521
Japan
Granted
Jun 05, 2014
Jun 03, 2015
Aug 27, 2020
EP 2017 516196
JP 2017-519522
Japan
Granted
Jun 05, 2014
Jun 03, 2015
Aug 27, 2020
EP 2017 516198
JP 2017-519522
Japan
Granted
Jun 05, 2014
Jun 03, 2015
Aug 27, 2020
Results CORE 1

Your investment leads to the approval of the first personalized diagnosis for progressive COPD by two independent clinical studies, the development of the first transgenic model system for COPD, as well as the identification of the most suitable candidates for causal treatment at the respective stage of COPD. In particular:

  1. Validation of biomarkers and targets derived from the COPD pilot study (first study conducted between 2007 and 2013) for diagnosis of progressive COPD by two prospective clinical studies required for approval.
  2. The validation study (Transgenion’s Clinical Study #2 planned 2024 – 2028) will validate the pulmonary biomarkers and targets and correlate the findings with new serum markers based on chip-based whole genome mRNA profiling.
  3. Preclinical study set #1: Screening and acquisition of preclinical data regarding suitable drug candidates for the first causal treatment of COPD based on the main target.
  4. Preclinical study set #2: Development of the first transgenic pulmonary model systems for COPD for evaluation of metabolic and intervention pathways based on the biomarkers and targets derived from Transgenion’s pilot study (Clinical Study #1).
  5. The Diagnostic Approval Study (Clinical Study #3, prospective multicenter Phase 2 trial planned 2025 – 2029) will seek authority approval for Transgenion’s new diagnostic test (Prediction of progressive COPD and Indication for new causal therapy).
  6. Registration of additional IP based on the results from the successful European FP7 project 'Resolve'.

Upcoming Events

14

Mar
22nd Lung Science Conference 2024
The ERS Lung Science Conference is at the forefront of basic and translational respiratory science and is an essential event for budding respiratory researchers.
Estoril, Portugal

17

Jun
World Respiratory Medicine Congress 2024
Three-day event bringing together experts in pulmonology and respiratory medicine for robust discussions on advancements and strategies in the field.
Barcelona, Spain

07

SEP
34th European Respiratory Society (ERS)
The European Respiratory Society Congress is an annual event that brings together the world’s respiratory experts to showcase all the latest advances in respiratory medicine and science.
Vienna, Austria

13

SEP
ESMO Congress 2024
The ESMO Congress is a globally influential oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world.
Barcelona, Spain

Get in Touch!

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.